机构：[1]Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, 100010, China[2]Department of Neurosurgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, 310009, China[3]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 100070, China首都医科大学附属天坛医院[4]Department of Neurosurgery, Shenzhen Second People’s Hospital, 518035, China深圳市康宁医院深圳医学信息中心[5]Department of Neurosurgery, Nanfang Hospital Southern Medical University, 510515, China[6]Department of Neurosurgery, Sun Yat-Sen University Cancer Center, 510060, China[7]Tumor Diagnosis & Treatment Center, The Sixth Medical Center of PLA General Hospital, 100048, China[8]Department of Neurosurgery, Xiangya Hospital Central South University, 410008, China[9]Department of Neurosurgery, The First Hospital of China Medical University, 110001, China[10]Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, 325000, China[11]Department of Neurosurgery, The Fourth Military University Tangdu Hospital, 710032, China[12]Department of Craniobasal Neurology, Sichuan Cancer Hospital & Institute, The Affiliated Cancer Hospital, School of Medicine,UESTC, 610041, China四川省肿瘤医院[13]Department of Neurosurgery, Southwest Hospital, The First Affiliated Hospital of Army Medical University, 400038, China[14]Department of Neurosurgery, The First Bethune Hospital of Jilin University, 130021, China[15]Department of Neurosurgery, People’s Hospital of Xinjiang Uygur Autonomous Region, 830001, China[16]Department of Radiotherapy, People’s Hospital of Xinjiang Uygur Autonomous Region, 830001, China[17]Department of Neurosurgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 310016, China[18]Department of Neurosurgery, Xinqiao Hospital of Army Medical University, 400037, China[19]Department of Neurosurgery, The First Affiliated Hospital of Fujian Medical University, 350005, China[20]Department of Neurosurgery, Tumor Hospital of Harbin Medical University, 150081, China[21]Department of Neurosurgery, Peking University First Hospital, 100034, China[22]Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, 150001, China[23]Department of Neurosurgery, Qilu Hospital of Shandong University, 250012, China[24]Department of Neurosurgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 200127, China[25]Department of Neurosurgery, General Hospital of Southern Theatre Command, 510010, China[26]Department of Neurosurgery, General Hospital of Eastern Theatre Command, 210002, China[27]Department of Neurosurgery, General Hospital of Northern Theatre Command, 110840, China
Aims: To determine how consistently Chinese glioblastoma multiforme (GBM) patients were treated according to the Stupp regimen. Patients and methods: The proportion of treatments conforming to the Stupp regimen and reasons for nonconformity were evaluated in 202 newly diagnosed GBM patients. Results: Only 15.8% of GBM patients received treatments compliant with the Stupp regimen. The main deviations were temozolomide dosages >75 mg/m(2) (58/120; 48.3%) and treatment durations <42 days (84/120; 70.0%) in the concomitant phase and temozolomide dosages <150 mg/m(2) (89/101; 88.1%) in the maintenance phase. Median overall survival (27.09 vs 18.21 months) and progression-free survival (14.27 vs 12.10 months) were longer in patients who received Stupp regimen-compliant treatments. Conclusion: Increased conformity to the Stupp regimen is needed for GBM patients in China. Lay abstract In 2005 the European Organization for Research and Treatment of Cancer 26981 study led to US FDA approval for the use of temozolomide in combination with radiotherapy to treat glioblastoma multiforme (GBM). The Stupp regimen consists of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks (a total of 60 Gy), plus concomitant daily temozolomide (75 mg/m(2)/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150-200 mg/m(2)/day for 5 days during each 28-day cycle). In 2012 the Chinese guidelines for the diagnosis and treatment of glioma of the CNS recommended the Stupp regimen as first-line therapy for newly diagnosed GBM. In the present study, compliance of GBM treatments with the Stupp regimen in 28 Chinese centers from 2012-2016 was evaluated. Only 15.8% of GBM patients received treatments compliant with the Stupp regimen. The main deviations related to temozolomide dosages and treatment durations in the concomitant and maintenance phases. Median overall survival (27.09 vs 18.21 months) and progression-free survival (14.27 vs 12.10 months) were longer in patients who received Stupp regimen-compliant treatments.
第一作者机构：[1]Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, 100010, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Wang Yu,Zhang Jianmin,Li Wenbin,et al.Guideline conformity to the Stupp regimen in patients with newly diagnosed glioblastoma multiforme in China[J].FUTURE ONCOLOGY.2021,17(33):4571-4582.doi:10.2217/fon-2021-0435.
APA：
Wang, Yu,Zhang, Jianmin,Li, Wenbin,Jiang, Taipeng,Qi, Songtao...&Wang, Renzhi.(2021).Guideline conformity to the Stupp regimen in patients with newly diagnosed glioblastoma multiforme in China.FUTURE ONCOLOGY,17,(33)
MLA：
Wang, Yu,et al."Guideline conformity to the Stupp regimen in patients with newly diagnosed glioblastoma multiforme in China".FUTURE ONCOLOGY 17..33(2021):4571-4582
